𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Methotrexate content in squamous cell carcinoma of the head and neck after low-dose methotrexate

✍ Scribed by Schifeling, David J. ;George, Todd ;McGuirt, Fred ;Capizzi, Robert L. ;Kamen, Barton A.

Publisher
John Wiley and Sons
Year
1994
Tongue
English
Weight
232 KB
Volume
22
Category
Article
ISSN
0098-1532

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Eleven patients with squamous carcinoma of the head and neck who were scheduled for surgical resection or endoscopic biopsy of tumor received 15 mg/m^2^ of methotrexate (MTX). Samples of tumor, normal mucosa, and plasma were obtained at surgery or endoscopy, 18‐24 hours after the last MTX dose. Tissue content and plasma concentration of MTX and folate were measured using sequential radioligand‐binding assays. Median MTX content was 50.0 pmol/g wet weight in tumor, 19.0 in normal mucosa, and <0.5 nM (pmol/ml) in plasma. Since dihydrofolate reductase (DHFR) content of human tumors has previously been shown to be less than 5 pmol enzyme/g wet weight, tumor MTX content exceeded expected DHFR content in all but one patient. These data support the concept that low doses of MTX saturate tumor DHFR and that, in this regard, dose escalation may have limited value. Β© 1994 Wiley‐Liss, Inc.

πŸ“œ SIMILAR VOLUMES

Sequential methotrexate–5-fluorouracil t
Sequential methotrexate–5-fluorouracil treatment of squamous cell carcinoma of the head and neck
✍ Ulrik Ringborg; GΓ–Sta Ewert; Jan Kinnman; Per-Gotthard Lundqvist; Hans Strander πŸ“‚ Article πŸ“… 1983 πŸ› John Wiley and Sons 🌐 English βš– 271 KB πŸ‘ 2 views

Thirty-six patients with squamous cell carcinoma of the head and neck were treated with sequential methotrexate-5-fluorouracil followed by leucovorin rescue. The frequency of objective tumor regression obtained was 64% (complete response + partial response) with 19% complete regression. In 20 not pr

Thirty-six-hour preoperative high-dose m
Thirty-six-hour preoperative high-dose methotrexate infusion in patients with squamous carcinoma of the head and neck
✍ Hande, K. R. ;Chretien, P. B. ;Elias, E. G. ;Goldberg, N. H. ;Brooks, A. E. ;Cha πŸ“‚ Article πŸ“… 1979 πŸ› John Wiley and Sons 🌐 English βš– 330 KB

Twenty 36-hour infusions of high-dose methotrexate were given preoperatively to 10 patients with head and neck cancer. Plasma methotrexate levels of greater than 1 X 10(-5) M were maintained for 36 hours and declined with primary and secondary plasma half-lives of 1.7 and 9.2 hours following the end

Combination chemotherapy with cisplatin,
Combination chemotherapy with cisplatin, methotrexate, bleomycin, and vincristine (CABO) in advanced squamous cell carcinoma of the head and neck
✍ Marcel Rozencweig; Pierre Dodion; Uta Bruntsch; Walter Gallmeier; Michel Clavel; πŸ“‚ Article πŸ“… 1984 πŸ› John Wiley and Sons 🌐 English βš– 547 KB

A combination of cisplatin, methotrexate, bleomycin, and vincristine (CABO) was assessed in advanced epidermoid head and neck cancer. Among 72 patients with recurrent or metastatic disease and measurable lesions, there were 9 complete and 27 partial responses for an overall response rate of 50%. The

Combination chemotherapy with methotrexa
Combination chemotherapy with methotrexate, bleomycin, and vincristine with or without cisplatin in advanced squamous cell carcinoma of the head and neck
✍ M. Clavel; F. Cognetti; P. Dodion; J. Wildiers; R. Rosso; A. Rossi; B. Gignoux; πŸ“‚ Article πŸ“… 1987 πŸ› John Wiley and Sons 🌐 English βš– 449 KB πŸ‘ 2 views

## For the EORTC Head and Neck Cooperative Group A total of 185 eligible patients with advanced inoperable squamous cell carcinoma of the head and neck were randomized into two groups; the cisplatin, methotrexate, bleomycin, and vincristine (CABO) group received cisplatin (50 mg/m2; day 4), methot